745 related articles for article (PubMed ID: 28241849)
1. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
2. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK).
Sánchez Y; Amrán D; Fernández C; de Blas E; Aller P
Int J Cancer; 2008 Sep; 123(5):1205-14. PubMed ID: 18546268
[TBL] [Abstract][Full Text] [Related]
3. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
5. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
[TBL] [Abstract][Full Text] [Related]
6. The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels.
Han YH; Moon HJ; You BR; Kim SZ; Kim SH; Park WH
Anticancer Res; 2009 Oct; 29(10):3837-44. PubMed ID: 19846917
[TBL] [Abstract][Full Text] [Related]
7. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.
Liu Y; Hock JM; Sullivan C; Fang G; Cox AJ; Davis KT; Davis BH; Li X
J Cell Biochem; 2010 Dec; 111(6):1546-55. PubMed ID: 20862710
[TBL] [Abstract][Full Text] [Related]
8. Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2.
Binet F; Girard D
J Leukoc Biol; 2008 Dec; 84(6):1613-22. PubMed ID: 18728151
[TBL] [Abstract][Full Text] [Related]
9. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases.
Sánchez Y; Calle C; de Blas E; Aller P
Chem Biol Interact; 2009 Nov; 182(1):37-44. PubMed ID: 19720055
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Ling S; Feng T; Ke Q; Fan N; Li L; Li Z; Dong C; Wang C; Xu F; Li Y; Wang L
Oncol Rep; 2014 Jun; 31(6):2611-8. PubMed ID: 24788596
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
Mandegary A; Torshabi M; Seyedabadi M; Amirheidari B; Sharif E; Ghahremani MH
Biomed Res Int; 2013; 2013():237543. PubMed ID: 24312908
[TBL] [Abstract][Full Text] [Related]
12. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
13. MAPK inhibitors and siRNAs differentially affect cell death and ROS levels in arsenic trioxide-treated human pulmonary fibroblast cells.
Park WH
Oncol Rep; 2012 May; 27(5):1611-8. PubMed ID: 22293863
[TBL] [Abstract][Full Text] [Related]
14. S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
Zhang MX; Gan W; Jing CY; Zheng SS; Yi Y; Zhang J; Xu X; Lin JJ; Zhang BH; Qiu SJ
Mol Carcinog; 2019 Jan; 58(1):19-30. PubMed ID: 30182496
[TBL] [Abstract][Full Text] [Related]
15. ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation.
Zhang X; Li X; Li X; Zheng L; Lei L
Tumori; 2015; 101(4):360-7. PubMed ID: 25983101
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
Chen L; Han F; Qu H; Yan H; Ren L; Yang S
Pharmazie; 2013 Feb; 68(2):117-23. PubMed ID: 23469683
[TBL] [Abstract][Full Text] [Related]
17. Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Zhu HQ; Ma JB; Song X; Gao HJ; Ma CQ; Chang H; Li HG; Liu FF; Lu J; Zhou X
Oncol Rep; 2016 Dec; 36(6):3488-3496. PubMed ID: 27779693
[TBL] [Abstract][Full Text] [Related]
18. The synergistic antitumor activity of arsenic trioxide and vitamin K2 in HL-60 cells involves increased ROS generation and regulation of the ROS-dependent MAPK signaling pathway.
Qu H; Tong D; Zhang Y; Kang K; Zhang Y; Chen L; Ren L
Pharmazie; 2013 Oct; 68(10):839-45. PubMed ID: 24273890
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; García-Marco JA; García-Pardo A
Oncotarget; 2016 Dec; 7(50):83359-83377. PubMed ID: 27829220
[TBL] [Abstract][Full Text] [Related]
20. Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
Shen L; Zhang G; Lou Z; Xu G; Zhang G
BMC Complement Altern Med; 2017 Feb; 17(1):106. PubMed ID: 28187727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
